Supreme Court dismisses plea of Novartis for patent of cancer drug

Discussion in 'Economy & Infrastructure' started by steel, Apr 1, 2013.

  1. steel

    steel Regular Member

    Joined:
    Sep 5, 2011
    Messages:
    42
    Likes Received:
    27
    The Supreme Court on Monday dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a serious blow to Western pharmaceutical firms who are increasingly focusing on India to drive sales.

    The decision also sets a benchmark for several intellectual property disputes in India, where many patented drugs are unaffordable for most of its 1.2 billion people.

    India's domestic drugs market is the 14th largest globally, but with annual growth of 13-14 per cent and the world's second biggest population, it has massive potential at a time when traditional developed markets have slowed down.


    The Supreme Court's landmark ruling is likely to affect several other companies and their branded medicines.

    Pfizer Inc's cancer drug Sutent and Roche Holding AG's hepatitis C treatment Pegasys lost their patented status in India last year, and Monday's ruling will make it tougher for them to win back patent protection.

    "Henceforth, multinational pharma companies are likely to want that their patents are first recognised in India before launch of a patented product," said Ameet Hariani, managing partner at Mumbai-based law firm Hariani & Co.

    Novartis has previously said that it needs legal certainty if it is to plan further investment in drug research in India.

    The ruling is a boost for healthcare activists who want the government to make medicines cheaper in a country where patented drugs constitute under 10 per cent of total drug sales.

    Novartis has been fighting since 2006 to win a patent for an amended form of Glivec. In 2009 it took its challenge against a law that bans patents on newer but not radically different forms of known drugs to the Supreme Court.

    India has refused protection for Glivec on the grounds that it is not a new medicine but an amended version of a known compound. By contrast, the newer form of Glivec has been patented in nearly 40 countries including the United States, Russia and China.

    The Supreme Court decided that Glivec does not satisfy the "novelty" aspect, Pravin Anand, lawyer for Novartis, told reporters.

    Shares in Novartis India Ltd, the Indian unit of the drugmaker, fell over 5 per cent after the verdict.

    Supreme Court dismisses plea of Novartis for patent of cancer drug - The Times of India
     
    Singh likes this.
  2.  
  3. Singh

    Singh Phat Cat Administrator

    Joined:
    Feb 23, 2009
    Messages:
    20,305
    Likes Received:
    8,270
    Location:
    011
    Excellent. The SC of India should allow copyright infringements in situations where lives are at risk.
    Let any Cancer drug not being sold in India due to IP/Cost etc. be allowed to be reproduced(generics) and sold at nominal rates.
     
    DivineHeretic likes this.
  4. DivineHeretic

    DivineHeretic Senior Member Senior Member

    Joined:
    Jan 1, 2013
    Messages:
    1,050
    Likes Received:
    1,183
    Location:
    Assam
    True that. The common man cannot afford a drug at Rs. 50000-150,000 per month. Especially if it can be produced at 1/10th that sum by generic producers. We are not a country with per capita income of $35,000, glad that the SC understands this, even though I suspect the govt. might
    Just to remind everyone how the drug companies try to scam everyone...

    http://health.india.com/diseases-co...compulsory-licence-for-leukaemia-drug-sought/

    The branded drug used to treat chronic myeloid leukaemia, a cancer of the white blood cells and the treatment costs Rs 1.6 lakh per month.
    The application which was filed on March 4, says that BDR Pharma will provide the treatment for Rs 8,100 per month.

    If SC grants these companies exclusive patents, the common man will die either from disease being unable to pay for medication, or will die of debt ridden stress.
     

Share This Page